Data gathered: April 15
Alternative Data for Nanobiotix
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 426 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
| Price | $3.33 |
| Target Price | Sign up |
| Volume | 752 |
| Market Cap | $158M |
| Year Range | $2.81 - $6 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Nanobiotix (NASDAQ:NBTX) Price Target Lowered to $8.00 at GuggenheimApril 5 - ETF Daily News |
 |
Nanobiotix price target lowered by $4 at Guggenheim, here's whyApril 4 - Thefly.com |
 |
Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call TranscriptApril 3 - SeekingAlpha |
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27 - GlobeNewswire |
|
|
Nanobiotix (NBTX) Expected to Announce Earnings on MondayMarch 23 - ETF Daily News |
|
Nanobiotix (NBTX) Expected to Announce Quarterly Earnings on MondayMarch 22 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 4.6M | 0 | 4.6M | -11M | -12M | 0.000 |
| Q1 '24 | 4.6M | 14M | 4.6M | -11M | -12M | |
| Q4 '23 | 0 | 0 | 0 | 0 | 0 | |
| Q3 '23 | 16M | 0 | 16M | -5.8M | 710,000 | |
| Q2 '23 | 1.6M | 740,000 | 910,000 | -28M | -28M |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Nanobiotix (NBTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Nanobiotix?
The Market Cap of Nanobiotix is $158M.
What is the current stock price of Nanobiotix?
Currently, the price of one share of Nanobiotix stock is $3.33.
How can I analyze the NBTX stock price chart for investment decisions?
The NBTX stock price chart above provides a comprehensive visual representation of Nanobiotix's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Nanobiotix shares. Our platform offers an up-to-date NBTX stock price chart, along with technical data analysis and alternative data insights.
Does NBTX offer dividends to its shareholders?
As of our latest update, Nanobiotix (NBTX) does not offer dividends to its shareholders. Investors interested in Nanobiotix should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Nanobiotix?
Some of the similar stocks of Nanobiotix are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.